Literature DB >> 11585870

Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody.

Z Yao1, K Garmestani, K J Wong, L S Park, E Dadachova, A Yordanov, T A Waldmann, W C Eckelman, C H Paik, J A Carrasquillo.   

Abstract

UNLABELLED: Monoclonal antibodies (mAbs) labeled with alpha-emitting radionuclides such as (211)At, (212)Bi, (213)Bi, and (212)Pb (which decays by beta-emission to its alpha-emitting daughter, (212)Bi) are being evaluated for their potential applications for cancer therapy. The fate of these radionuclides after cells are targeted with mAbs is important in terms of dosimetry and tumor detection.
METHODS: In this study, we attached various radionuclides that result in alpha-emissions to T101, a rapidly internalizing anti-CD5 mAb. We then evaluated the catabolism and cellular retention and compared them with those of (125)I- and (111)In-labeled T101. T101 was labeled with (211)At, (125)I, (205,6)Bi, (111)In, and (203)Pb. CD5 antigen-positive cells, peripheral blood mononuclear cells (PBMNC), and MOLT-4 leukemia cells were used. The labeled T101 was incubated with the cells for 1 h at 4 degrees C for surface labeling. Unbound activity was removed and 1 mL medium added. The cells were then incubated at 37 degrees C for 0, 1, 2, 4, 8, and 24 h. The activity on the cell surface that internalized and the activity on the cell surface remaining in the supernatant were determined. The protein in the supernatant was further precipitated by methanol for determining protein-bound and non-protein-bound radioactivity. Sites of internal cellular localization of radioactivity were determined by Percoll gradient centrifugation.
RESULTS: All radiolabeled antibodies bound to the cells were internalized rapidly. After internalization, (205,6)Bi, (203)Pb, and (111)In radiolabels were retained in the cell, with little decrease of cell-associated radioactivity. However, (211)At and (125)I were released from cells rapidly ((211)At < (125)I) and most of the radioactivity in the supernatant was in a non-protein-bound form. Intracellular distribution of radioactivity revealed a transit of the radiolabel from the cell surface to the lysosome. The catabolism patterns of MOLT-4 cells and PBMNC were similar.
CONCLUSION: (211)At catabolism and release from cells were somewhat similar to that of (125)I, whereas (205,6)Bi and (203)Pb showed prolonged cell retention similar to that of (111)In. These catabolism differences may be important in the selection of alpha-radionuclides for radioimmunotherapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11585870

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  15 in total

Review 1.  Continuing pursuit for ideal systemic anticancer radiotherapeutics.

Authors:  Marlein Miranda Cona; Huaijun Wang; Junjie Li; Yuanbo Feng; Feng Chen; Peter de Witte; Alfons Verbruggen; Yicheng Ni
Journal:  Invest New Drugs       Date:  2011-10-18       Impact factor: 3.850

Review 2.  Targeted alpha-therapy: past, present, future?

Authors:  Martin W Brechbiel
Journal:  Dalton Trans       Date:  2007-09-11       Impact factor: 4.390

3.  Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.

Authors:  Sarah M Cheal; Blesida Punzalan; Michael G Doran; Michael J Evans; Joseph R Osborne; Jason S Lewis; Pat Zanzonico; Steven M Larson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-07       Impact factor: 9.236

Review 4.  Cancer radioimmunotherapy with alpha-emitting nuclides.

Authors:  Olivier Couturier; Stéphane Supiot; Marie Degraef-Mougin; Alain Faivre-Chauvet; Thomas Carlier; Jean-François Chatal; François Davodeau; Michel Cherel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05       Impact factor: 9.236

5.  A Radiolabeled Fully Human Antibody to Human Aspartyl (Asparaginyl) β-Hydroxylase Is a Promising Agent for Imaging and Therapy of Metastatic Breast Cancer.

Authors:  Ekaterina Revskaya; Zewei Jiang; Alfred Morgenstern; Frank Bruchertseifer; Muctarr Sesay; Susan Walker; Steven Fuller; Michael S Lebowitz; Claudia Gravekamp; Hossein A Ghanbari; Ekaterina Dadachova
Journal:  Cancer Biother Radiopharm       Date:  2017-03       Impact factor: 3.099

6.  Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma.

Authors:  Meili Zhang; Zhengsheng Yao; Kayhan Garmestani; Sarah Yu; Carolyn K Goldman; Chang H Paik; Martin W Brechbiel; Jorge A Carrasquillo; Thomas A Waldmann
Journal:  Cancer Biother Radiopharm       Date:  2009-06       Impact factor: 3.099

Review 7.  Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.

Authors:  Greg M Thurber; Michael M Schmidt; K Dane Wittrup
Journal:  Adv Drug Deliv Rev       Date:  2008-04-24       Impact factor: 15.470

8.  Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts.

Authors:  Meili Zhang; Zhuo Zhang; Kayhan Garmestani; Jody Schultz; Donald B Axworthy; Carolyn K Goldman; Martin W Brechbiel; Jorge A Carrasquillo; Thomas A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-04       Impact factor: 11.205

Review 9.  Applications of heteronuclear NMR spectroscopy in biological and medicinal inorganic chemistry.

Authors:  Luca Ronconi; Peter J Sadler
Journal:  Coord Chem Rev       Date:  2008-01-26       Impact factor: 22.315

10.  Noninvasive in vivo imaging of CD4 cells in simian-human immunodeficiency virus (SHIV)-infected nonhuman primates.

Authors:  Michele Di Mascio; Chang H Paik; Jorge A Carrasquillo; Jin-Soo Maeng; Beom-Su Jang; In Soo Shin; Sharat Srinivasula; Russ Byrum; Achilles Neria; William Kopp; Marta Catalfamo; Yoshiaki Nishimura; Keith Reimann; Malcolm Martin; H Clifford Lane
Journal:  Blood       Date:  2009-05-05       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.